Skip to content

Cancers & treatments

News & evidence

Living with cancer

Learn & contribute

Loading

A public, cited, editable map of oncology: technologies, targets, products, companies, institutions, pathways, trials, pairings, roadmaps, and ideas. One page per object, with a plain-language TL;DR on every page.

Work in progress. Every fact on this site is being built and checked in the open and may be incomplete, out of date, or wrong. You must do your own research and verify anything here at its primary source before relying on it. Nothing on this site is medical advice; decisions belong with you and your clinicians.

OnCo is an information resource, not medical advice. Nothing here replaces a conversation with a qualified clinician. Never delay care because of something you read here; in an emergency, call your local emergency services. Terms of use

Browse by cancer
Tags
Search
Connections
For me
Navigator
Biomarker matrix
Calculators
Interactions
Decision aids
Checkpoint side effects
Tumour board
Compare
Counts by category
Rankings
Timeline
Year by year
Query builder
Graph explorer
Saved
Body map

Cancers & treatments

News & evidence

Institutions & people

Institutions
Universities
Trial leadership
People
Heroes and heroines
Companies
Startups
Requests for startups
Investors
Company scorecards
Trial sponsors
Manufacturing map
Countries
United States deep dive
India deep dive
China deep dive
Germany deep dive
Israel deep dive
United Kingdom deep dive
Cases by country
Funding flows

Living with cancer

For me
The first 60 days
Appointment prep pack
Side effects
Symptom to test
Report reader
Survivorship planner
Second opinion
Financial help
Free in oncology
Paying for care in the US
NHS coverage
Paying for care in India
Coverage rankings
Cutting cancer care costs
Diet, exercise and lifestyle
Supportive care
Recovery and rejuvenation
Complementary and supportive approaches
Hair loss and regrowth
What comes back after treatment
Heroes and heroines

Learn & contribute

Reading paths
About & methodology
Roadmap
Gaps to fill
Coverage of the field
Review queue
Reviewer roster
Contributors
Idea votes
Teaching packs
Weekly issue
Suggest an edit
Answer quality
Data dictionary
Build on OnCo
Open API
Open data
Open tools
Open source in oncology
The software of oncology
GitHub

© 2026 OnCo. Code MIT. The data are free for individual and educational use with the attribution “Data from OnCo (onco.cc)”, under CC BY-NC 4.0. Commercial use must contact us to pay for the data. Commercial licences. Made with heart and soul by Jude Gomila .

About and methodology Corrections Open API Tags Terms of use Privacy policy GitHub

Loading

Home
People
Fangliang (Frank) Zhang

peoplePerson

Fangliang (Frank) Zhang

Frank Zhang founded GenScript and its cell therapy spin-out Legend Biotech, whose Nanjing team invented the myeloma CAR-T that became Carvykti.

Also called: Frank Zhang · 张方亮

Overview Connected4

Overview

Zhang founded GenScript in New Jersey in 2002 and moved it to Nanjing; Legend Biotech, spun out in 2014, developed the llama-derived BCMA CAR-T LCAR-B38M (LEGEND-2), partnered it with Janssen in 2017 and listed on Nasdaq in 2020; ciltacabtagene autoleucel was approved by the FDA in 2022 and the NMPA in 2024. He stepped back from executive roles in 2021.

Role

Founder and former Chairman, Legend Biotech; former Chairman, GenScript Biotech

Specialisms

Cell therapyBiotech leadershipGene synthesis

Profiles

Legend Biotech

Connected

Similar pages

Key paper
CARTITUDE-1: cilta-cel, a BCMA CAR-T, in heavily pretreated myeloma
Shares Legend Biotech, CARTITUDE-1, Ciltacabtagene autoleucel.
Person
Jesús G. Berdeja
Shares CARTITUDE-1, Ciltacabtagene autoleucel.
Trial
CARTITUDE-4
Shares Legend Biotech, LEGEND-2, Ciltacabtagene autoleucel.
Institution
Comprehensive Cancer Center Mainfranken, University Hospital Würzburg
Shares Legend Biotech, Ciltacabtagene autoleucel.
Key paper
CARTITUDE-4: cilta-cel CAR-T versus standard combinations after one to three prior lines of myeloma therapy
Shares Legend Biotech, Ciltacabtagene autoleucel.
Technology
Autologous CAR-T manufacturing, batch by batch
Shares Legend Biotech, Ciltacabtagene autoleucel.

drugs

ApprovedCAR-T (BCMA)

Ciltacabtagene autoleucel · Carvykti

companies

trials

CARTITUDE-1 LEGEND-2

ProvenanceLast edited 2026-09-10 · Jude Gomila · China deep dive · diff · file

Sources & links

Legend Biotech

Data

Follow this page

Wrong or missing?

Propose a change with a source. Organisations can update their own records. Every suggestion is reviewed, safety-checked and validated before it goes live; nothing is edited directly.

Suggest an editDiscuss start a thread

Out of date?
How review works

Products

Ciltacabtagene autoleucel

Companies

Legend Biotech

Trials

LEGEND-2
CARTITUDE-1

Not yet reviewedSee the review queue and roster.

Model panel commentary is coming to this page: machine commentary, not clinical review.

Machine-readable versions of Fangliang (Frank) Zhang

JSON record with neighbours
Markdown context for language models
RDF Turtle for this record (its triples, relations and owl:sameAs; the IRI of this record is https://onco.cc/people/zhang-fangliang/)
All people as JSON
RDF N-Triples for the whole corpus
Search index: id, kind, name, TL;DR and route for every record
OpenAPI 3.1 description
API root and meta.json
llms.txt

MCP server: npx -y onco-mcp, tools search, get_entity, list_kind, ask, context, compare. This record is get_entity or context with id zhang-fangliang.

WebMCP tools registered on this page: onco_search, onco_get_entity.